Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntuitive Investment Group Regulatory News (IIG)

Share Price Information for Intuitive Investment Group (IIG)

Share Price is delayed by 15 minutes
Get Live Data
280.00    -5.00 (-1.82%)
Bid:
270.00
Ask:
290.00
Spread: 20.00 (7.407%)
Market Cap: £647.54m
IIG Live PriceLast checked at - London Stock Exchange

Intraday Intuitive Investment Group Share Chart

Director Dealing

24 Jan 2022 08:45

RNS Number : 3658Z
Intuitive Investments Group plc
24 January 2022
 

Intuitive Investments Group plc

("IIG" or the "Company")

 

Director Dealing

Intuitive Investments Group plc (AIM:IIG), ("IIG" or the "Company"), announces that Mr David Evans, Executive Chairman of Intuitive Investment Group, has transferred 1,742,000 ordinary shares of 1p each in the Company ("Ordinary Shares") from a nominee account to his SIPP. The Ordinary Shares were transferred at a price of 17.75p and remain beneficially owned by Mr Evans.

 Accordingly, Mr Evans's total holding in the Company remains unchanged at 5,000,000 Ordinary Shares, representing approximately 12.37 per cent. of the Company's issued share capital.

For further information, please contact:

Intuitive Investments Group plc

www.iigplc.com

David Evans, Executive Chairman

Robert Naylor, CEO

Via Walbrook PR

 

 

SP Angel Corporate Finance LLP - Nominated Adviser

+44 (0) 20 3470 0470

Jeff Keating / David Hignell / Kasia Brzozowska

 

Turner Pope Investments (TPI) Ltd - Broker

+44 (0) 20 3657 0050

Andrew Thacker / James Pope

 

 

 

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

Paul McManus/ Sam Allen

+44 (0) 7980 541 893 / +44 (0) 7502 558 258

 

About Intuitive Investments Group plc

The Company is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGIGDBXSDDGDS
Date   Source Headline
11th Jul 20237:00 amRNSNotice of General Meeting to approve Proposals
11th Jul 20237:00 amRNSIIG appoints Sir Nigel Rudd as its next Chairman
5th Jul 20233:46 pmRNSFORM 8.3 - Yourgene Health Plc
29th Jun 20237:00 amRNSInterim report for the six months to 31 March 2023
31st May 20237:00 amRNSTotal Voting Rights
24th May 20237:00 amRNSReorganisation and Deferred Consideration
26th Apr 20234:57 pmRNSHolding(s) in Company
17th Jan 202311:19 amRNSResult of AGM and Directorate Change
11th Jan 202310:00 amRNSInvestment in Yourgene Health plc
21st Dec 20227:00 amRNSFinal Results
7th Nov 20222:05 pmRNSSecond Price Monitoring Extn
7th Nov 20222:00 pmRNSPrice Monitoring Extension
5th Aug 20227:00 amRNSInvestment in PneumoWave Limited
26th May 20227:00 amRNSUpdate on Sanondaf
25th May 20227:00 amRNSHalf-year Report
20th Apr 202211:13 amRNSDispensation from Rule 9 of the Code
4th Apr 202211:13 amRNSTotal Voting Rights
8th Mar 20223:39 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSSubscription
25th Feb 202212:11 pmRNSInvestment & Appointment of Non-Executive Chair
14th Feb 202212:59 pmRNSChange of Registered Office
14th Feb 20227:00 amRNSInvestment in Ocutec Limited
24th Jan 20228:45 amRNSDirector Dealing
30th Dec 202110:58 amRNSResult of AGM
20th Dec 20217:00 amRNSChange of Registered Office
6th Dec 20217:00 amRNSFinal Results and Notice of AGM
29th Nov 20217:00 amRNSChange of Adviser
5th Nov 202110:12 amRNSHolding(s) in Company
28th Oct 20211:38 pmRNSNotice of Results
15th Oct 20218:01 amRNSLight Science Technologies Holdings - Floatation
12th Oct 20219:48 amRNSLight Science Technologies - Intention To Float
20th Sep 20218:04 amRNSLight Science Technologies Holdings - update
15th Sep 20217:00 amRNSInvestment in Momentum Bioscience Limited
20th Aug 20213:40 pmRNSDirector Dealing
29th Jun 202110:56 amRNSInvestment in Midatech Pharma PLC
2nd Jun 20217:00 amRNSInterim report
28th May 20212:18 pmRNSInvestment in Trellus Health plc
4th May 20217:00 amRNSInvestment in The Electrospinning Company Limited
9th Apr 202111:01 amRNSIssue of Shares and Total Voting Rights
1st Apr 20217:00 amRNSInvestment in Axol Bioscience Ltd
31st Mar 20214:18 pmRNSInvestment in Altair
31st Mar 202112:00 pmRNSInvestment in CardiNor AS
17th Mar 20217:00 amRNSInvestment in Polarean Imaging plc
16th Mar 20217:00 amRNSInvestment in Micrima Limited
1st Mar 20217:00 amRNSInvestment in Shield Therapeutics plc
22nd Feb 20217:00 amRNSInvestment in Yourgene Health plc
12th Feb 202111:41 amRNSProposed Investment in Kromek Pharma plc
8th Feb 202111:08 amRNSHolding(s) in Company
3rd Feb 20217:00 amRNSProposed Investment in Evgen Pharma plc
29th Jan 20217:00 amRNSPortfolio company BioQ Pharma receives CE mark

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.